A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

Desai, J; Fong, P; Moreno, V; Frentzas, S; Meniawy, T; Markman, B; Voskoboynik, M; Rahman, T; Budha, N; Wu, J; Marlow, J; Yang, S; Calvo, E; Martin-Liberal, J

Author(s): Desai, J; Fong, P; Moreno, V; Frentzas, S; Meniawy, T; Markman, B; Voskoboynik, M; Rahman, T; Budha, N; Wu, J; Marlow, J; Yang, S; Calvo, E; Martin-Liberal, J;
Details: Publication Year 2023-04,Volume 128,Issue #8,Page 1418-1428
Journal Title: British Journal of Cancer
Publication Type: Research article
Abstract: BACKGROUND: Many patients do not respond or eventually relapse on treatment with programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors due to secondary or acquired resistance; therefore, there is a need to investigate novel PD-1/PD-L1 inhibitors. METHODS: This open-label, non-randomised study investigated the safety and anti-tumour activity of BGB-A333, a PD-L1 inhibitor, alone and in combination with tislelizumab in patients with advanced solid tumours with progression during/after standard therapy. The primary objectives were to determine the recommended Phase 2 dose (RP2D), safety and tolerability for BGB-A333 alone and in combination with tislelizumab (Phase 1a/1b) and to determine the overall response rate (ORR) with BGB-A333 plus tislelizumab (Phase 2). RESULTS: Overall, 39 patients across Phase 1a (N = 15), 1b (N = 12) and 2 (N = 12) were enroled. In Phase 1a, an RP2D of 1350 mg was determined. In Phase 1a and 1b/2, serious treatment-emergent adverse events (TEAEs) were reported in five and eight patients, respectively. Two patients experienced TEAEs that led to death. In Phase 2, the ORR was 41.7% (n = 5/12; 95% confidence interval: 15.17%, 72.33%). CONCLUSIONS: TEAEs reported with BGB-A333 were consistent with other PD-L1 inhibitors. Encouraging preliminary anti-tumour activity was observed with BGB-A333 in combination with tislelizumab. CLINICAL TRIAL REGISTRATION: NCT03379259.
Publisher: Springer Nature
Keywords: Humans; *Immune Checkpoint Inhibitors; *B7-H1 Antigen; Programmed Cell Death 1 Receptor; Neoplasm Recurrence, Local/drug therapy; Antibodies, Monoclonal/adverse effects
Department(s): Medical Oncology
PubMed ID: 36797356
Publisher's Version: https://doi.org/10.1038/s41416-022-02128-3
Open Access at Publisher's Site: https://doi.org/10.1038/s41416-022-02128-3
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-07-19 07:47:31

Last Modified: 2023-07-19 07:47:59